Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879228 | 0.83 | LMNA (0.43) | KMT2A | |
| SCHEMBL413824 | 0.75 | NOTUM (0.41) | — | |
| SCHEMBL13003306 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL13534637 | 0.72 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL14456848 | 0.72 | CHRNB2 (0.65) | KMT2ASMN1; SMN2 | |
| SCHEMBL12879227 | 0.72 | MAPT (0.30) | SMN1; SMN2 | |
| SCHEMBL12575353 | 0.72 | PHGDH (0.38) | MEN1KMT2A | |
| SCHEMBL6726839 | 0.72 | GPR119 (0.37) | — | |
| SCHEMBL890089 | 0.72 | CYP1A2 (0.44) | MEN1KMT2ACHRM1SMN1; SMN2 | |
| SCHEMBL11842319 | 0.72 | SMN1; SMN2 (0.35) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486974-B2 | Efficient aspirin prodrugs | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2013-07-16 | — | — | US | disclosed |
| US-20110046182-A1 | EFFICIENT ASPIRIN PRODRUGS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046182-A1 | EFFICIENT ASPIRIN PRODRUGS | COX15, PTGS1, CYP3A43 | CHRM2 2638/4885MEN1 3818/4885CYP2D6 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.